Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jennifer Mink"'
Autor:
John Nemunaitis, James P. O'Brien, Pallavi Sachdev, Corina Andresen, Cynthia Bedell, Jennifer Mink, Min Ren, Robert Shumaker, Lucy Xu, Goldy C. George, Ly M. Nguyen, Michael A. Davies, Kevin B. Kim, Siqing Fu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Razelle Kurzrock, David S. Hong
Supplementary Tables S1 and S2. Supplementary Table 1. Univariate Cox proportional hazard model analysis using baseline and change in levels of biomarkers with PFS Supplementary Table 2. Multivariate Cox proportional hazard model analysis using basel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f763894bc770dba6ac95ef69cfb9c40
https://doi.org/10.1158/1078-0432.22458195
https://doi.org/10.1158/1078-0432.22458195
Autor:
John Nemunaitis, James P. O'Brien, Pallavi Sachdev, Corina Andresen, Cynthia Bedell, Jennifer Mink, Min Ren, Robert Shumaker, Lucy Xu, Goldy C. George, Ly M. Nguyen, Michael A. Davies, Kevin B. Kim, Siqing Fu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Razelle Kurzrock, David S. Hong
Purpose: This “3+3” phase I study evaluated the safety, biologic, and clinical activity of lenvatinib, an oral multikinase inhibitor, in patients with solid tumors.Experimental Design: Ascending doses of lenvatinib were administered per os twice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3839d647413c4a841ebad871c41ed31e
https://doi.org/10.1158/1078-0432.c.6523866.v1
https://doi.org/10.1158/1078-0432.c.6523866.v1
Autor:
Michael A. Davies, Corina Andresen, Jennifer J. Wheler, Goldy C. George, Lucy Xu, Razelle Kurzrock, Min Ren, Gerald Steven Falchook, Kevin B. Kim, Siqing Fu, James P. O'Brien, David S. Hong, John Nemunaitis, Jennifer Mink, Robert Shumaker, Cynthia Bedell, Pallavi Sachdev, Ly M. Nguyen, Aung Naing
Publikováno v:
Clinical Cancer Research. 21:4801-4810
Purpose: This “3+3” phase I study evaluated the safety, biologic, and clinical activity of lenvatinib, an oral multikinase inhibitor, in patients with solid tumors. Experimental Design: Ascending doses of lenvatinib were administered per os twice
Autor:
Min Ren, Corina Andresen, James P. O'Brien, Jennifer Mink, Gerald S. Falchook, David S. Hong, John Nemunaitis, Razelle Kurzrock, Ly M. Nguyen
Publikováno v:
Journal of Clinical Oncology. 30:8594-8594
8594 Background: Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. In phase I studies of lenvatinib partial responses were observed in melanoma as well as thyroid, endometrial, and renal cancers. Metho
Autor:
David S. Hong, Thomas J. Evans, Min Ren, R. Kurzrock, Hilary Glen, Corina Andresen, J.H.M. Schellens, D. S. Boss, James P. O'Brien, John Nemunaitis, Jennifer Mink
Publikováno v:
Journal of Clinical Oncology. 29:8527-8527
8527 Background: E7080 is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRβ. In phase I studies of E7080, DLTs were hypertension and proteinuria and common toxicities included grade 1-2 fatigue, anorexia, nausea, wei
Autor:
Aung Naing, Jennifer Mink, N. N. Senzer, David S. Hong, Jennifer J. Wheler, B. S. Koetz, John Nemunaitis, R. Kurzrock, W. Hanekom, Min Ren
Publikováno v:
Journal of Clinical Oncology. 28:2540-2540
2540 Background: E7080 is a potent, orally administered, receptor tyrosine kinase inhibitor of KDR, VEGFR1, VEGFR3, FGFR2, and RET. Antiangiogenic and antiproliferative activity were seen in human ...